{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:52:09Z","timestamp":1761094329912,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.bbmt.2017.07.015","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T07:15:22Z","timestamp":1500966922000},"page":"1870-1878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients"],"prefix":"10.1016","volume":"23","author":[{"given":"Katharina","family":"Lisenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Wuchter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Hansberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Mangatter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Benner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.07.015_bib0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/978-94-007-5416-4_22","article-title":"The challenge of systemic immunoglobulin light-chain amyloidosis (Al)","volume":"65","author":"Palladini","year":"2012","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/bmt.2011.152","article-title":"Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis","volume":"47","author":"Schonland","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0020","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ddmec.2004.11.008","article-title":"Immune mechanisms of AL amyloidosis","volume":"1","author":"Perfetti","year":"2004","journal-title":"Drug Discov Today Dis Mech"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0030","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0035","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0040","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +\/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial","volume":"139","author":"Cohen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0050","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bmt.1705848","article-title":"Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)","volume":"40","author":"Gertz","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.2008.07327.x","article-title":"Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone","volume":"143","author":"Lebovic","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0060","first-page":"1635","article-title":"Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis","volume":"91","author":"Perfetti","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2141.2004.05232.x","article-title":"High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study","volume":"127","author":"Perz","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0070","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation","volume":"110","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.bmt.1705746","article-title":"Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis","volume":"40","author":"Sanchorawala","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","article-title":"Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis","volume":"109","author":"Wechalekar","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0090","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","article-title":"Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients","volume":"101","author":"Moreau","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0095","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study","volume":"128","author":"Bochtler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0100","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blade","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.bmt.1705627","article-title":"Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma","volume":"39","author":"Gertz","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0115","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0120","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.bbmt.2012.07.016","article-title":"Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment","volume":"18","author":"Cowan","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0125","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bmt.1704826","article-title":"Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis","volume":"35","author":"Oran","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00508-005-0505-x","article-title":"Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity","volume":"118","author":"Worel","year":"2006","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0135","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1537-2995.2005.00597.x","article-title":"Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis","volume":"45","author":"Perotti","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0140","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bmt.1702643","article-title":"Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)","volume":"26","author":"Gertz","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jca.21323","article-title":"Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma","volume":"29","author":"Hundemer","year":"2014","journal-title":"J Clin Apher"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0160","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0165","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/j.seminhematol.2004.05.006","article-title":"The role of stem cell transplantation in chronic lymphocytic leukemia","volume":"41","author":"Rizouli","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0170","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/blood.V85.2.588.588","article-title":"Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients","volume":"85","author":"Tricot","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0175","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.ajkd.2006.03.036","article-title":"Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy","volume":"47","author":"Sucker","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11096-009-9354-4","article-title":"Severe ifosfamide-induced neurotoxicity: a case report","volume":"32","author":"Ramos Linares","year":"2010","journal-title":"Pharm World Sci"},{"issue":"suppl 2","key":"10.1016\/j.bbmt.2017.07.015_bib0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000073352","article-title":"Neurological toxicity of ifosfamide","volume":"65","author":"Nicolao","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0190","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2165\/00002512-200724110-00008","article-title":"Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature","volume":"24","author":"Brunello","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0195","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2010.32.5878","article-title":"Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies","volume":"29","author":"Moreau","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2895.x","article-title":"Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation","volume":"78","author":"Klaus","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0205","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.bmt.1703575","article-title":"Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation","volume":"29","author":"Allan","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0210","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1200\/JCO.2000.18.6.1360","article-title":"Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy","volume":"18","author":"Siena","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0215","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1182\/blood.V86.10.3961.bloodjournal86103961","article-title":"An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy","volume":"86","author":"Weaver","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0220","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0225","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0230","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bmt.2015.190","article-title":"Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation","volume":"50","author":"Uy","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0235","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.1998.16.4.1547","article-title":"Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma","volume":"16","author":"Desikan","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0240","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ajh.24453","article-title":"Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation","volume":"91","author":"Hwa","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0245","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/bmt.2011.216","article-title":"European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of Stem Cell Mobilization","volume":"47","author":"Hubel","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0250","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/14653249.2010.530652","article-title":"Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor","volume":"13","author":"Taubert","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0255","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/bmt.2010.249","article-title":"Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program","volume":"46","author":"Hubel","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0260","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3109\/14653240903121245","article-title":"A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study","volume":"11","author":"Fruehauf","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0265","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0270","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","article-title":"AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data","volume":"41","author":"Calandra","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0275","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/13506129.2015.1104295","article-title":"Mobilization of peripheral blood hematopoietic stem cells by granulocyte-colony stimulating factor and plerixafor in patients with cardiac AL amyloidosis","volume":"22","author":"Galli","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.bbmt.2017.07.015_bib0280","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/13506129.2014.900486","article-title":"Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series","volume":"21","author":"Lee","year":"2014","journal-title":"Amyloid"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117306067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117306067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:00:54Z","timestamp":1761058854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117306067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1083879117306067"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.015","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}